- Home
- JYD vs VYNE Comparison
JYD vs VYNE Comparison
Compare JYD & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- VYNE
- Stock Information
- Founded
- JYD 2001
- VYNE 2003
- Country
- JYD China
- VYNE United States
- Employees
- JYD N/A
- VYNE N/A
- Industry
- JYD Oil Refining/Marketing
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- VYNE Health Care
- Exchange
- JYD Nasdaq
- VYNE Nasdaq
- Market Cap
- JYD 17.8M
- VYNE 16.0M
- IPO Year
- JYD 2023
- VYNE 2018
- Fundamental
- Price
- JYD $0.19
- VYNE $1.44
- Analyst Decision
- JYD
- VYNE Strong Buy
- Analyst Count
- JYD 0
- VYNE 2
- Target Price
- JYD N/A
- VYNE $6.25
- AVG Volume (30 Days)
- JYD 1.8M
- VYNE 1.3M
- Earning Date
- JYD 07-15-2025
- VYNE 08-13-2025
- Dividend Yield
- JYD N/A
- VYNE N/A
- EPS Growth
- JYD N/A
- VYNE N/A
- EPS
- JYD N/A
- VYNE N/A
- Revenue
- JYD $77,444,271.00
- VYNE $605,000.00
- Revenue This Year
- JYD N/A
- VYNE $42.51
- Revenue Next Year
- JYD N/A
- VYNE N/A
- P/E Ratio
- JYD N/A
- VYNE N/A
- Revenue Growth
- JYD 13.54
- VYNE 43.03
- 52 Week Low
- JYD $0.09
- VYNE $0.85
- 52 Week High
- JYD $8.00
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- JYD 34.27
- VYNE 56.49
- Support Level
- JYD $0.18
- VYNE $1.20
- Resistance Level
- JYD $0.22
- VYNE $1.49
- Average True Range (ATR)
- JYD 0.01
- VYNE 0.22
- MACD
- JYD 0.01
- VYNE 0.03
- Stochastic Oscillator
- JYD 21.21
- VYNE 53.15
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.